Eintrag weiter verarbeiten
Targeted Modulation of MGMT: Clinical Implications
Gespeichert in:
| Zeitschriftentitel: | Clinical Cancer Research |
|---|---|
| Personen und Körperschaften: | , |
| In: | Clinical Cancer Research, 12, 2006, 2, S. 328-331 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Association for Cancer Research (AACR)
|
| Schlagwörter: |
| author_facet |
Liu, Lili Gerson, Stanton L. Liu, Lili Gerson, Stanton L. |
|---|---|
| author |
Liu, Lili Gerson, Stanton L. |
| spellingShingle |
Liu, Lili Gerson, Stanton L. Clinical Cancer Research Targeted Modulation of MGMT: Clinical Implications Cancer Research Oncology |
| author_sort |
liu, lili |
| spelling |
Liu, Lili Gerson, Stanton L. 1078-0432 1557-3265 American Association for Cancer Research (AACR) Cancer Research Oncology http://dx.doi.org/10.1158/1078-0432.ccr-05-2543 <jats:title>Abstract</jats:title> <jats:p>O6-Methylguanine DNA methyltransferase (MGMT) has been studied for &gt;20 years as a gene that is associated with the mutagenicity and cytotoxicity induced by either methylating carcinogens or alkylating (methylating and chloroethylating) therapeutic agents. Pioneering studies of alkylating agents identified alkylated guanine at the O6 position, the substrate of MGMT, as a potentially promutagenic and lethal toxic DNA lesion. MGMT plays a prominent role in DNA adduct repair that limits the mutagenic and cytotoxic effect of alkylating agents. Because of its role in cancer etiology and chemotherapy resistance, MGMT is of particular interest. In this article, the clinical effect of MGMT expression and targeted modulation of MGMT will be summarized.</jats:p> Targeted Modulation of MGMT: Clinical Implications Clinical Cancer Research |
| doi_str_mv |
10.1158/1078-0432.ccr-05-2543 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8xMDc4LTA0MzIuY2NyLTA1LTI1NDM |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8xMDc4LTA0MzIuY2NyLTA1LTI1NDM |
| institution |
DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 |
| imprint |
American Association for Cancer Research (AACR), 2006 |
| imprint_str_mv |
American Association for Cancer Research (AACR), 2006 |
| issn |
1078-0432 1557-3265 |
| issn_str_mv |
1078-0432 1557-3265 |
| language |
English |
| mega_collection |
American Association for Cancer Research (AACR) (CrossRef) |
| match_str |
liu2006targetedmodulationofmgmtclinicalimplications |
| publishDateSort |
2006 |
| publisher |
American Association for Cancer Research (AACR) |
| recordtype |
ai |
| record_format |
ai |
| series |
Clinical Cancer Research |
| source_id |
49 |
| title |
Targeted Modulation of MGMT: Clinical Implications |
| title_unstemmed |
Targeted Modulation of MGMT: Clinical Implications |
| title_full |
Targeted Modulation of MGMT: Clinical Implications |
| title_fullStr |
Targeted Modulation of MGMT: Clinical Implications |
| title_full_unstemmed |
Targeted Modulation of MGMT: Clinical Implications |
| title_short |
Targeted Modulation of MGMT: Clinical Implications |
| title_sort |
targeted modulation of mgmt: clinical implications |
| topic |
Cancer Research Oncology |
| url |
http://dx.doi.org/10.1158/1078-0432.ccr-05-2543 |
| publishDate |
2006 |
| physical |
328-331 |
| description |
<jats:title>Abstract</jats:title>
<jats:p>O6-Methylguanine DNA methyltransferase (MGMT) has been studied for &gt;20 years as a gene that is associated with the mutagenicity and cytotoxicity induced by either methylating carcinogens or alkylating (methylating and chloroethylating) therapeutic agents. Pioneering studies of alkylating agents identified alkylated guanine at the O6 position, the substrate of MGMT, as a potentially promutagenic and lethal toxic DNA lesion. MGMT plays a prominent role in DNA adduct repair that limits the mutagenic and cytotoxic effect of alkylating agents. Because of its role in cancer etiology and chemotherapy resistance, MGMT is of particular interest. In this article, the clinical effect of MGMT expression and targeted modulation of MGMT will be summarized.</jats:p> |
| container_issue |
2 |
| container_start_page |
328 |
| container_title |
Clinical Cancer Research |
| container_volume |
12 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792346198251667463 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T17:35:21.353Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Targeted+Modulation+of+MGMT%3A+Clinical+Implications&rft.date=2006-01-15&genre=article&issn=1557-3265&volume=12&issue=2&spage=328&epage=331&pages=328-331&jtitle=Clinical+Cancer+Research&atitle=Targeted+Modulation+of+MGMT%3A+Clinical+Implications&aulast=Gerson&aufirst=Stanton+L.&rft_id=info%3Adoi%2F10.1158%2F1078-0432.ccr-05-2543&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792346198251667463 |
| author | Liu, Lili, Gerson, Stanton L. |
| author_facet | Liu, Lili, Gerson, Stanton L., Liu, Lili, Gerson, Stanton L. |
| author_sort | liu, lili |
| container_issue | 2 |
| container_start_page | 328 |
| container_title | Clinical Cancer Research |
| container_volume | 12 |
| description | <jats:title>Abstract</jats:title> <jats:p>O6-Methylguanine DNA methyltransferase (MGMT) has been studied for &gt;20 years as a gene that is associated with the mutagenicity and cytotoxicity induced by either methylating carcinogens or alkylating (methylating and chloroethylating) therapeutic agents. Pioneering studies of alkylating agents identified alkylated guanine at the O6 position, the substrate of MGMT, as a potentially promutagenic and lethal toxic DNA lesion. MGMT plays a prominent role in DNA adduct repair that limits the mutagenic and cytotoxic effect of alkylating agents. Because of its role in cancer etiology and chemotherapy resistance, MGMT is of particular interest. In this article, the clinical effect of MGMT expression and targeted modulation of MGMT will be summarized.</jats:p> |
| doi_str_mv | 10.1158/1078-0432.ccr-05-2543 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8xMDc4LTA0MzIuY2NyLTA1LTI1NDM |
| imprint | American Association for Cancer Research (AACR), 2006 |
| imprint_str_mv | American Association for Cancer Research (AACR), 2006 |
| institution | DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1 |
| issn | 1078-0432, 1557-3265 |
| issn_str_mv | 1078-0432, 1557-3265 |
| language | English |
| last_indexed | 2024-03-01T17:35:21.353Z |
| match_str | liu2006targetedmodulationofmgmtclinicalimplications |
| mega_collection | American Association for Cancer Research (AACR) (CrossRef) |
| physical | 328-331 |
| publishDate | 2006 |
| publishDateSort | 2006 |
| publisher | American Association for Cancer Research (AACR) |
| record_format | ai |
| recordtype | ai |
| series | Clinical Cancer Research |
| source_id | 49 |
| spelling | Liu, Lili Gerson, Stanton L. 1078-0432 1557-3265 American Association for Cancer Research (AACR) Cancer Research Oncology http://dx.doi.org/10.1158/1078-0432.ccr-05-2543 <jats:title>Abstract</jats:title> <jats:p>O6-Methylguanine DNA methyltransferase (MGMT) has been studied for &gt;20 years as a gene that is associated with the mutagenicity and cytotoxicity induced by either methylating carcinogens or alkylating (methylating and chloroethylating) therapeutic agents. Pioneering studies of alkylating agents identified alkylated guanine at the O6 position, the substrate of MGMT, as a potentially promutagenic and lethal toxic DNA lesion. MGMT plays a prominent role in DNA adduct repair that limits the mutagenic and cytotoxic effect of alkylating agents. Because of its role in cancer etiology and chemotherapy resistance, MGMT is of particular interest. In this article, the clinical effect of MGMT expression and targeted modulation of MGMT will be summarized.</jats:p> Targeted Modulation of MGMT: Clinical Implications Clinical Cancer Research |
| spellingShingle | Liu, Lili, Gerson, Stanton L., Clinical Cancer Research, Targeted Modulation of MGMT: Clinical Implications, Cancer Research, Oncology |
| title | Targeted Modulation of MGMT: Clinical Implications |
| title_full | Targeted Modulation of MGMT: Clinical Implications |
| title_fullStr | Targeted Modulation of MGMT: Clinical Implications |
| title_full_unstemmed | Targeted Modulation of MGMT: Clinical Implications |
| title_short | Targeted Modulation of MGMT: Clinical Implications |
| title_sort | targeted modulation of mgmt: clinical implications |
| title_unstemmed | Targeted Modulation of MGMT: Clinical Implications |
| topic | Cancer Research, Oncology |
| url | http://dx.doi.org/10.1158/1078-0432.ccr-05-2543 |